Caxton Corporation’s Aclaris Therapeutics ACRS Stock Holding History

Caxton Corporation’s Portfolio ACRS Stock Details ACRS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q4	–	Sell	-19,473	Closed	-$133K	–	13
2023 Q3	$133K	Buy	+19,473	New	+$166K	0.51%	7
2019 Q1	–	Sell	-61,264	Closed	-$453K	–	27
2018 Q4	$453K	Buy	61,264 +21,509	+54%	+$222K	0.55%	14
2018 Q3	$577K	Buy	39,755 +20,241	+104%	+$347K	0.53%	15
2018 Q2	$390K	Sell	19,514 -1,628	-8%	-$30.1K	0.14%	15
2018 Q1	$370K	Buy	21,142 +3,148	+17%	+$66.7K	0.4%	17
2017 Q4	$444K	Buy	17,994 +7,818	+77%	+$190K	0.54%	13
2017 Q3	$263K	Buy	10,176 +38	+0.4%	+$1.02K	0.27%	15
2017 Q2	$275K	Sell	10,138 -3,125	-24%	-$85K	0.43%	11
2017 Q1	$395K	Buy	13,263 +22	+0.2%	+$634	1.13%	6
2016 Q4	$359K	Buy	+13,241	New	+$338K	1.22%	6

Other funds holding ACRS

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BCLSI

Bain Capital Life Sciences Investors Boston, Massachusetts $1.11B AUM 171.34% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

RSCM

Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

VCIM

Velan Capital Investment Management Alpharetta, Georgia $160M AUM 517.12% 1-Year Est. Return

Caxton Corporation's ACRS Position: Q4 2023 in Review

Caxton Corporation sold out of Aclaris Therapeutics (ACRS) in Q4 2023, closing a stake of 19,473 shares — an estimated $133K sold.

Caxton Corporation first reported a position in ACRS in Q4 2016 and held it in 10 quarters. The position peaked at $577K in Q3 2018. 107 funds tracked by Wall St. Rank hold ACRS as of Q4 2023.

Caxton Corporation reported no remaining Aclaris Therapeutics position as of Q4 2023 after selling out during the quarter.
Caxton Corporation sold 19,473 Aclaris Therapeutics shares in Q4 2023, an estimated $133K.
Caxton Corporation first reported a position in Aclaris Therapeutics in Q4 2016 and held it in 10 quarters.
Caxton Corporation's Aclaris Therapeutics position peaked at $577K in Q3 2018.
107 funds tracked by Wall St. Rank held Aclaris Therapeutics as of Q4 2023.

Based on Caxton Corporation's 13F filing for Q4 2023, filed 14 Feb 2024.